Concert Pharmaceuticals

$11.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (+3.22%) Today
$0.00 (0.00%) As of 6:07 PM UTC after-hours

Why Robinhood?

You can buy or sell CNCE and other stocks, options, and ETFs commission-free!

About CNCE

Concert Pharmaceuticals, Inc. Common Stock, also called Concert Pharmaceuticals, is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. The listed name for CNCE is Concert Pharmaceuticals, Inc. Common Stock.

CEO
Roger D. Tung
Employees
70
Headquarters
Lexington, Massachusetts
Founded
2006
Market Cap
348.48M
Price-Earnings Ratio
Dividend Yield
Average Volume
100.91K
High Today
$11.73
Low Today
$10.62
Open Price
$11.00
Volume
78.31K
52 Week High
$13.09
52 Week Low
$5.47

Collections

CNCE Earnings

-$0.93
-$0.62
-$0.31
-$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like